Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study

BackgroundPostoperative adjuvant transcatheter arterial chemoembolization (TACE) following curative hepatectomy has been reported to improve the clinical outcomes of hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI), but more endeavors are required to achieve greater clinical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jianqiang Cai, Jianjun Zhao, Defang Liu, Huangfan Xie, Hailong Qi, Junfan Ma, Zhongjie Sun, Hong Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	hepatocellular carcinoma microvascular invasion adjuvant therapy Tcm treatment clinical study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/095dbad9420e448d8cff6e5c5a1efd5e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:095dbad9420e448d8cff6e5c5a1efd5e
record_format	dspace
spelling	oai:doaj.org-article:095dbad9420e448d8cff6e5c5a1efd5e2021-12-03T13:32:43ZEfficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study2234-943X10.3389/fonc.2021.781029https://doaj.org/article/095dbad9420e448d8cff6e5c5a1efd5e2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.781029/fullhttps://doaj.org/toc/2234-943XBackgroundPostoperative adjuvant transcatheter arterial chemoembolization (TACE) following curative hepatectomy has been reported to improve the clinical outcomes of hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI), but more endeavors are required to achieve greater clinical benefit. Central memory T-cell (Tcm) self-transfusion has shown superior antitumor activity in several preclinical studies; however, clinical studies are rare. The aim of this study was to evaluate the clinical benefit and safety of combination treatment with Tcm self-transfusion and TACE as adjuvant treatment in HCC patients with MVI after curative hepatectomy.MethodsFrom October 2016 to September 2018, primary HCC patients with histologically confirmed MVI who underwent curative hepatectomy at the Cancer Hospital of the Chinese Academy of Medical Sciences were recruited for this study. The patients were divided into a Tcm group (combined Tcm self-transfusion with TACE treatment) or a control group (TACE treatment alone) according to their willingness. The recurrence-free survival (RFS), quality-of-life (QOL) score, and adverse events of each patient were recorded within 2 years.ResultsA total of 52 patients were enrolled, and 48 were eligible for the final data analysis. The median follow-up time was 20.5 months (95% CI: 17.05–22.55 months). The median RFS time was 9.5 months in the control group; the cutoff date was not reached in the Tcm group (when the follow-up duration was 12 months, p = 0.049, HR = 0.40; 95% CI: 0.16–0.99). Compared with the control group, 1- and 2-year RFS rates were higher in the Tcm group (72.0% vs. 46.4% and 58.18% vs. 39.14%, respectively). Multivariate analysis did not indicate that Tcm treatment was an independent prognostic factor associated with HCC recurrence (p = 0.107, HR = 2.312; 95% CI: 0.835–6.400), which might be due to the small sample size of this study. Nevertheless, Tcm treatment effectively improved a reduced QOL due to HCC and liver function injury. Finally, the safety profile of Tcm treatment in this study was good, without any serious adverse events.ConclusionsThis pilot study showed that Tcm self-transfusion combined with TACE treatment might be a beneficial adjuvant therapy with good safety for primary HCC patients with MVI after curative hepatectomy.Trial registration numberNCT03575806Jianqiang CaiJianjun ZhaoDefang LiuHuangfan XieHailong QiHailong QiJunfan MaZhongjie SunHong ZhaoFrontiers Media S.A.articlehepatocellular carcinomamicrovascular invasionadjuvant therapyTcm treatmentclinical studyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatocellular carcinoma microvascular invasion adjuvant therapy Tcm treatment clinical study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hepatocellular carcinoma microvascular invasion adjuvant therapy Tcm treatment clinical study Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jianqiang Cai Jianjun Zhao Defang Liu Huangfan Xie Hailong Qi Hailong Qi Junfan Ma Zhongjie Sun Hong Zhao Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study
description	BackgroundPostoperative adjuvant transcatheter arterial chemoembolization (TACE) following curative hepatectomy has been reported to improve the clinical outcomes of hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI), but more endeavors are required to achieve greater clinical benefit. Central memory T-cell (Tcm) self-transfusion has shown superior antitumor activity in several preclinical studies; however, clinical studies are rare. The aim of this study was to evaluate the clinical benefit and safety of combination treatment with Tcm self-transfusion and TACE as adjuvant treatment in HCC patients with MVI after curative hepatectomy.MethodsFrom October 2016 to September 2018, primary HCC patients with histologically confirmed MVI who underwent curative hepatectomy at the Cancer Hospital of the Chinese Academy of Medical Sciences were recruited for this study. The patients were divided into a Tcm group (combined Tcm self-transfusion with TACE treatment) or a control group (TACE treatment alone) according to their willingness. The recurrence-free survival (RFS), quality-of-life (QOL) score, and adverse events of each patient were recorded within 2 years.ResultsA total of 52 patients were enrolled, and 48 were eligible for the final data analysis. The median follow-up time was 20.5 months (95% CI: 17.05–22.55 months). The median RFS time was 9.5 months in the control group; the cutoff date was not reached in the Tcm group (when the follow-up duration was 12 months, p = 0.049, HR = 0.40; 95% CI: 0.16–0.99). Compared with the control group, 1- and 2-year RFS rates were higher in the Tcm group (72.0% vs. 46.4% and 58.18% vs. 39.14%, respectively). Multivariate analysis did not indicate that Tcm treatment was an independent prognostic factor associated with HCC recurrence (p = 0.107, HR = 2.312; 95% CI: 0.835–6.400), which might be due to the small sample size of this study. Nevertheless, Tcm treatment effectively improved a reduced QOL due to HCC and liver function injury. Finally, the safety profile of Tcm treatment in this study was good, without any serious adverse events.ConclusionsThis pilot study showed that Tcm self-transfusion combined with TACE treatment might be a beneficial adjuvant therapy with good safety for primary HCC patients with MVI after curative hepatectomy.Trial registration numberNCT03575806
format	article
author	Jianqiang Cai Jianjun Zhao Defang Liu Huangfan Xie Hailong Qi Hailong Qi Junfan Ma Zhongjie Sun Hong Zhao
author_facet	Jianqiang Cai Jianjun Zhao Defang Liu Huangfan Xie Hailong Qi Hailong Qi Junfan Ma Zhongjie Sun Hong Zhao
author_sort	Jianqiang Cai
title	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study
title_short	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study
title_full	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study
title_fullStr	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study
title_full_unstemmed	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study
title_sort	efficacy and safety of central memory t cells combined with adjuvant therapy to prevent recurrence of hepatocellular carcinoma with microvascular invasion: a pilot study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/095dbad9420e448d8cff6e5c5a1efd5e
work_keys_str_mv	AT jianqiangcai efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT jianjunzhao efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT defangliu efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT huangfanxie efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT hailongqi efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT hailongqi efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT junfanma efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT zhongjiesun efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy AT hongzhao efficacyandsafetyofcentralmemorytcellscombinedwithadjuvanttherapytopreventrecurrenceofhepatocellularcarcinomawithmicrovascularinvasionapilotstudy
_version_	1718373188453269504

Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study

Ejemplares similares